The aim of our research is to determine the risk of bone disease in hypercalciuric kidney stone formers and their families by establishing an algorithm that takes into account bone mineral density (BMD), demographic characteristics diet history, and urine and serum chemistries, including markers of bone turnover. The algorithm will allow us to determine which hypercalciurics need clinical evaluation for osteoporosis and will form the basis of a disease management product. In the process of creating this algorithm, we will be the first to determine the prevalence of bone disease in hypercalciuric stone formers and their families and over time make some estimates of incidence rates. A longer- term goal of our research is to study the genetic underpinnings of osteoporosis and nephrolithasis in these families.

Proposed Commercial Applications

Litholink provides disease management services for kidney stone patients. We hope to use the algorithm developed in this research to expand out services to include bone disease management in kidney stone forming patients and their families.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44DK059086-03
Application #
6622487
Study Section
Special Emphasis Panel (ZRG1-UROL (17))
Program Officer
Chang, Debuene
Project Start
2002-05-01
Project End
2005-06-30
Budget Start
2003-05-01
Budget End
2005-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$357,180
Indirect Cost
Name
Litholink Corporation
Department
Type
DUNS #
878190107
City
Chicago
State
IL
Country
United States
Zip Code
60612
Goodman, Jeffrey W; Asplin, John R; Goldfarb, David S (2009) Effect of two sports drinks on urinary lithogenicity. Urol Res 37:41-6
Asplin, John R; Coe, Fredric L (2007) Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 177:565-9
Goldfarb, David S; Modersitzki, Frank; Asplin, John R (2007) A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2:745-9
Wolf, Joshua; Asplin, John R; Goldfarb, David S (2006) Chitosan does not reduce post-prandial urinary oxalate excretion. Urol Res 34:227-30
Goldfarb, D S; Coe, F L; Asplin, J R (2006) Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 69:1041-7
Asplin, J R; Donahue, S; Kinder, J et al. (2006) Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int 70:1463-7
Pramanik, Rocky; Asplin, John R; Lindeman, Christina et al. (2004) Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol 232:137-43